View in EDS

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.

Saved in:
Bibliographic Details
Title: PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
Authors: Kristeleit R; University College London Cancer Institute, London, UK. rebecca.kristeleit@gstt.nhs.uk.; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. rebecca.kristeleit@gstt.nhs.uk.; Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. rebecca.kristeleit@gstt.nhs.uk., Leary A; Gustave Roussy, Villejuif, France., Oaknin A; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitario Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Redondo A; Medical Oncology Department, La Paz University Hospital-IdiPAZ, Madrid, Spain., George A; The Institute of Cancer Research, London, UK.; Royal Marsden NHS Foundation Trust, London, UK., Chui S; Product Development Oncology, Genentech Inc., South San Francisco, CA, USA., Seiller A; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Liste-Hermoso M; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Willis J; Product Development Safety, Roche Products Ltd, Welwyn Garden City, UK., Shemesh CS; Clinical Pharmacology Oncology, Genentech Inc, South San Francisco, CA, USA., Xiao J; Clovis Oncology, San Francisco, CA, USA., Lin KK; Clovis Oncology, San Francisco, CA, USA., Molinero L; Translational Medicine, Genentech Inc., South San Francisco, CA, USA., Guan Y; Translational Medicine, Genentech Inc., South San Francisco, CA, USA., Ray-Coquard I; Centre Leon Bérard, HESPER laboratory EA 7425, Université Claude Bernard Lyon Est, Lyon, France., Mileshkin L; Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.
Source: British journal of cancer [Br J Cancer] 2024 Sep; Vol. 131 (5), pp. 820-831. Date of Electronic Publication: 2024 Jul 06.
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study
Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38971950
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kristeleit+R%22">Kristeleit R</searchLink>; University College London Cancer Institute, London, UK. rebecca.kristeleit@gstt.nhs.uk.; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. rebecca.kristeleit@gstt.nhs.uk.; Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. rebecca.kristeleit@gstt.nhs.uk.<br /><searchLink fieldCode="AU" term="%22Leary+A%22">Leary A</searchLink>; Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Oaknin+A%22">Oaknin A</searchLink>; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitario Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Redondo+A%22">Redondo A</searchLink>; Medical Oncology Department, La Paz University Hospital-IdiPAZ, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22George+A%22">George A</searchLink>; The Institute of Cancer Research, London, UK.; Royal Marsden NHS Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Chui+S%22">Chui S</searchLink>; Product Development Oncology, Genentech Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Seiller+A%22">Seiller A</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Liste-Hermoso+M%22">Liste-Hermoso M</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Willis+J%22">Willis J</searchLink>; Product Development Safety, Roche Products Ltd, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Shemesh+CS%22">Shemesh CS</searchLink>; Clinical Pharmacology Oncology, Genentech Inc, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Xiao+J%22">Xiao J</searchLink>; Clovis Oncology, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Lin+KK%22">Lin KK</searchLink>; Clovis Oncology, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Molinero+L%22">Molinero L</searchLink>; Translational Medicine, Genentech Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Guan+Y%22">Guan Y</searchLink>; Translational Medicine, Genentech Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ray-Coquard+I%22">Ray-Coquard I</searchLink>; Centre Leon Bérard, HESPER laboratory EA 7425, Université Claude Bernard Lyon Est, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Mileshkin+L%22">Mileshkin L</searchLink>; Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220370635%22">British journal of cancer</searchLink> [Br J Cancer] 2024 Sep; Vol. 131 (5), pp. 820-831. <i>Date of Electronic Publication: </i>2024 Jul 06.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group+on+behalf+of+Cancer+Research+UK%22">Nature Publishing Group on behalf of Cancer Research UK </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0370635 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1532-1827 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200070920%22">00070920 </searchLink><i>NLM ISO Abbreviation: </i>Br J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38971950
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41416-024-02776-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 820
    Titles:
      – TitleFull: PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kristeleit R
      – PersonEntity:
          Name:
            NameFull: Leary A
      – PersonEntity:
          Name:
            NameFull: Oaknin A
      – PersonEntity:
          Name:
            NameFull: Redondo A
      – PersonEntity:
          Name:
            NameFull: George A
      – PersonEntity:
          Name:
            NameFull: Chui S
      – PersonEntity:
          Name:
            NameFull: Seiller A
      – PersonEntity:
          Name:
            NameFull: Liste-Hermoso M
      – PersonEntity:
          Name:
            NameFull: Willis J
      – PersonEntity:
          Name:
            NameFull: Shemesh CS
      – PersonEntity:
          Name:
            NameFull: Xiao J
      – PersonEntity:
          Name:
            NameFull: Lin KK
      – PersonEntity:
          Name:
            NameFull: Molinero L
      – PersonEntity:
          Name:
            NameFull: Guan Y
      – PersonEntity:
          Name:
            NameFull: Ray-Coquard I
      – PersonEntity:
          Name:
            NameFull: Mileshkin L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2024 Sep
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1532-1827
          Numbering:
            – Type: volume
              Value: 131
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: British journal of cancer
              Type: main
ResultId 1